Deletion of the epigenetic factor lysine methyltransferase 5C (KMT5C) promotes resistance to multiple EGFR inhibitors, including erlotinib, gefitinib, afatinib, and osimertinib, in NSCLC via LINC01510-mediated MET upregulation (LINC01510/MET axis) (Pal et al., 2022). Here, KMT5C is linked to non-small cell lung carcinoma.